Johnson & Johnson’s single-dose COVID-19 vaccine has received emergency use approval in India, health minister Mansukh Mandaviya said in a tweet.
The US pharmaceutical giant had applied for emergency use approval of its vaccine, the company had said on Friday. With this, India adds 5 vaccines to the approved list. The other four are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, and Moderna.
The shot will be brought to India through a supply agreement with homegrown vaccine maker Biological E Ltd, J&J had said.
“We are pleased to announce that on 7th August 2021, the Government of India issued Emergency Use Authorization (EUA) for the Johnson & Johnson COVID-19 single-dose vaccine in India, to prevent COVID in individuals 18 years of age and older,” a Johnson & Johnson India spokesperson said.
Studies have shown that the Johnson & Johnson vaccine is 66 percent effective in preventing cases of moderate to severe illness and 85 percent effective against severe cases of COVID-19. It completely prevented hospitalizations and death four weeks after inoculation, according to studies.